Aflibercept
- Generic Name
- Aflibercept
- Brand Names
- Eylea, Zaltrap, Yesafili
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 862111-32-8
- Unique Ingredient Identifier
- 15C2VL427D
- Background
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15%...
- Indication
The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).
...
- Associated Conditions
- Branch Retinal Vein Occlusion With Macular Edema, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Macular Edema With Central Retinal Vein Occlusions, Metastatic Colorectal Cancer (CRC), Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD), Retinopathy of Prematurity (ROP)
- Associated Therapies
- -
Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 268
- Registration Number
- NCT00851084
- Locations
- 🇦🇺
Sanofi-Aventis Investigational Site Number 036001, Hunter Region Mail Centre, Australia
🇩🇪Sanofi-Aventis Investigational Site Number 276001, Hannover, Germany
🇪🇸Sanofi-Aventis Investigational Site Number 724002, Sabadell, Spain
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00794417
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States
🇺🇸Kentucky Cancer Clinic, Hazard, Kentucky, United States
Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
- Conditions
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2014-05-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 61
- Registration Number
- NCT00650923
- Locations
- 🇺🇸
University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States
🇺🇸Adult Brain Tumor Consortium, Baltimore, Maryland, United States
🇺🇸University of California at Los Angeles (UCLA ), Los Angeles, California, United States
Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 25
- Registration Number
- NCT00644124
- Locations
- 🇫🇷
Sanofi-Aventis Administrative Office, Paris, France
Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-08-22
- Last Posted Date
- 2016-07-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1224
- Registration Number
- NCT00519285
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 75
- Registration Number
- NCT00407654
- Locations
- 🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 63
- Registration Number
- NCT00390234
- Locations
- 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Vancouver General Hospital, Vancouver, British Columbia, Canada
🇨🇦McGill University Department of Oncology, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.